Cerebrospinal fluid (CSF) studies consistently show that CSF levels of amyloid-beta 1–42 (Aβ42) are reduced and tau levels increased prior to the onset of cognitive decline related to Alzheimer’s disease (AD). Here, MAPT is linked to Alzheimer disease.